Candidemia in Immunocompromised Patients: Dental Diagnosis, Treatment, and Nursing Care-An Updated Review
Year: 2026
Type: article
Abstract: Background: Candidemia is a major healthcare-associated bloodstream infection associated with substantial morbidity and mortality, particularly among critically ill and immunocompromised patients. Its management remains challenging because of diagnostic delays, increasing antifungal resistance, and differences in the epidemiology of Candida species across geographical regions. Aim: This review examines the epidemiology, antifungal susceptibility, diagnostic approaches, and current therapeutic strategies for candidemia, with emphasis on emerging resistance patterns and clinical management challenges. Methods: Relevant literature was reviewed to summarize the distribution of Candida species, regional antifungal resistance profiles, and advances in diagnostic methods. The review also evaluates conventional blood cultures, molecular techniques, next-generation sequencing, T2 Candida, MALDI-TOF, non-culture-based biomarkers, and biosensors. Therapeutic approaches, including antifungal prophylaxis, empirical and targeted treatment, vascular catheter removal, ophthalmological assessment, therapeutic monitoring, and emerging antifungal agents, were also examined. Results: Non-albicans Candida species are increasingly contributing to candidemia, with substantial geographical variation in antifungal susceptibility. Although blood cultures remain the diagnostic reference standard, their limited sensitivity and delayed results support the use of rapid molecular and biomarker-based techniques. Echinocandins remain the preferred initial treatment for many non-neutropenic patients with candidemia. However, treatment outcomes are influenced by species identification, antifungal susceptibility, infection site, pharmacokinetic and pharmacodynamic factors, and timely source control. New agents, including rezafungin and fosmanogepix, offer potential therapeutic alternatives. Conclusion: Improved outcomes require early diagnosis, appropriate antifungal selection, source control, and individualized management guided by microbiological findings and patient characteristics.
DOI: 10.64483/202631869
Authors: Amal Mohammed Abdullah Ibn Mandeel, Aishah Hassan Ali Magrashi, Mashael Hussain Albalushei, Amal Saif Alsubaei, Waad Saad Aldossari, Aisha Marie Alsayed, Salmah Mansour Alazmi, Athyaha Hanaif Okashan Alruwaili, Wushaylah Qasem Ali Ahmadi, Fatima Qasim Ali Ahmadi, Hanan Abdulrahman Abdulah Ali, Shafega Ali Shajri
Institutions: Ministry of Health, East Jeddah Hospital
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: candidemia, immunocompromised patients, Candida species, antifungal resistance, antifungal susceptibility, non-albicans Candida, blood culture, molecular diagnosis, MALDI-TOF mass spectrometry, biosensors, echinocandins, antifungal prophylaxis, antifungal agents, rezafungin, fosmanogepix, source control
Open Access status: hybrid
OpenAlex ID: W7236572554
